If you have inflammatory bowel disease (IBD), you have probably heard your gastroenterologist or dietitian mention “the microbiome” as though it were one simple thing. It is not. Your large intestine hosts a vast community of bacteria, and one group within it spends its time producing butyrate, a compound that appears to play a meaningful role in keeping the colon lining calm and intact.
What are butyrate-making microbes?
Butyrate-producing bacteria break down dietary fibre into short-chain fatty acids (SCFAs), a family that includes butyrate, propionate, and acetate. Butyrate is most closely linked to colon health because it is the preferred fuel source for colonocytes, the cells lining the large bowel. These bacteria are not present in the same numbers in everyone’s gut, and their levels seem to vary with diet, medication history, and disease state.
Why butyrate matters for gut inflammation
The colon lining relies on a steady energy supply to repair itself and maintain a tight, selective barrier between gut contents and nearby immune cells. Butyrate is thought to supply much of that energy. When levels fall, colonocytes may become undernourished, the barrier can grow more permeable, and immune cells beneath it may be more easily triggered into inflammation. This matters for IBD, since both Crohn’s disease and ulcerative colitis involve a lining that struggles to stay intact and an immune system that overreacts.
Key mechanisms
Faecalibacterium prausnitzii
One of the most abundant, well-studied butyrate producers in a healthy gut. Studies show people with Crohn’s disease or ulcerative colitis tend to have lower levels of this bacterium, with lower levels also linked to higher relapse risk after surgery or during a flare. It is thought to calm gut immune activity, partly through butyrate and partly through other compounds it releases.
Roseburia species
Another major fibre-fermenting, butyrate-producing group. Stool studies repeatedly show reduced Roseburia in people with ulcerative colitis compared with those without it. Since this bacterium depends heavily on dietary fibre, its numbers can drop further when eating is restricted, as often happens during a flare.
Eubacterium rectale
A key contributor to overall colonic butyrate output, thriving in a diverse, fibre-rich gut. Its reduced presence has been observed alongside lower microbial diversity overall, a pattern common in IBD. A less diverse community generally produces less butyrate, which may help explain why gut barrier function is harder to maintain during active disease.
Fibre fermentation and short-chain fatty acid production
Butyrate-producing bacteria need dietary fibre, particularly the type that resists digestion in the small intestine and reaches the colon intact, as raw material. When fibre intake is consistently low, whether through choice, reduced appetite, or a restrictive eating pattern during a flare, less substrate is available for fermentation, and butyrate output can fall.
The gut lining and immune signalling
Beyond fuelling colonocytes, butyrate is thought to interact with immune cell receptors in ways that encourage a more regulated, less reactive gut immune response, sometimes described as supporting immune tolerance: the immune system recognising harmless bacteria without mounting a full inflammatory response. This is of particular interest in IBD, where the ability to distinguish friend from threat appears disrupted.
It is worth being clear that lower levels of these bacteria do not confirm active inflammation, and normal levels do not rule it out. Microbiome patterns are associative, not diagnostic, and symptoms like pain, urgency, or altered bowel habit do not always match inflammation seen on scans or endoscopy. Microbiome support is complementary to, not a substitute for, the medical treatment prescribed by your IBD team.
Practical Takeaways
- Discuss your individual fibre tolerance with your dietitian, particularly during and after a flare, rather than removing fibre indefinitely.
- Introduce fibre-containing foods gradually when your gut is settled, giving fermenting bacteria time to adjust.
- Avoid assuming every gut symptom reflects active inflammation; flag persistent changes with your IBD team.
- Track which foods you tolerate well over time, since tolerance can shift between remission and flare.
- Continue prescribed IBD medication as directed, even when symptoms improve, since microbiome changes work alongside treatment, not in place of it.
Conclusion
Butyrate-producing bacteria appear to support a healthy colon lining and a more regulated immune response, and their numbers often seem reduced in people with Crohn’s disease or ulcerative colitis. This remains an active, evolving area of research rather than settled science, and individual gut environments vary considerably. Long-term stability in IBD is more likely to come from consistent, personalised dietary patterns built up gradually than from short-term changes aimed at any single bacterial group. Make any dietary adjustments in partnership with your gastroenterologist or dietitian, particularly during periods of active disease.
References
- Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275-1283. doi:10.1136/gutjnl-2013-304833
- Vieira-Silva S, Sabino J, Valles-Colomer M, et al. Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses. Nat Microbiol. 2019;4(11):1826-1831. doi:10.1038/s41564-019-0483-9
- Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189-200. doi:10.1080/19490976.2015.1134082
- Venegas DP, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277. doi:10.3389/fimmu.2019.00277
- Pituch-Zdanowska A, Banaszkiewicz A, Albrecht P. The role of dietary fibre in inflammatory bowel disease. Prz Gastroenterol. 2015;10(3):135-141. doi:10.5114/pg.2015.52753
- Zhao H, Zhou W, Yao Y, et al. Butyrate in inflammatory bowel disease therapy. Gastroenterol Rep. 2021;9(2):91-98. doi:10.1093/gastro/goab006
- Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. J Gastroenterol. 2015;50(5):495-507. doi:10.1007/s00535-015-1064-1
- Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1-10. doi:10.1007/s12328-017-0813-5
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.